No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.
Immunological backbone of uveal melanoma: is there a rationale for immunotherapy? / Rossi, Ernesto; Schinzari, Giovanni; Zizzari, Ilaria Grazia; Maiorano, Brigida Anna; Pagliara, Monica Maria; Sammarco, Maria Grazia; Fiorentino, Vincenzo; Petrone, Gianluigi; Cassano, Alessandra; Rindi, Guido; Bria, Emilio; Blasi, Maria Antonietta; Nuti, Marianna; Tortora, Giampaolo. - In: CANCERS. - ISSN 2072-6694. - 11:8(2019), p. 1055. [10.3390/cancers11081055]
Immunological backbone of uveal melanoma: is there a rationale for immunotherapy?
Zizzari, Ilaria Grazia;Petrone, Gianluigi;Nuti, Marianna;
2019
Abstract
No standard treatment has been established for metastatic uveal melanoma (mUM). Immunotherapy is commonly used for this disease even though UM has not been included in phase III clinical trials with checkpoint inhibitors. Unfortunately, only a minority of patients obtain a clinical benefit with immunotherapy. The immunological features of mUM were reviewed in order to understand if immunotherapy could still play a role for this disease.| File | Dimensione | Formato | |
|---|---|---|---|
|
Petrone_Uveal-melanoma.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.5 MB
Formato
Adobe PDF
|
1.5 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
